 Mark Clements
Concepts (455)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 85 | 2023 | 104 | 26.590 |
Why?
| | Blood Glucose | 36 | 2023 | 55 | 6.090 |
Why?
| | Insulin | 28 | 2023 | 50 | 5.600 |
Why?
| | Hypoglycemic Agents | 26 | 2023 | 29 | 4.840 |
Why?
| | Hypoglycemia | 17 | 2023 | 22 | 4.790 |
Why?
| | Blood Glucose Self-Monitoring | 25 | 2023 | 27 | 4.730 |
Why?
| | Humans | 121 | 2023 | 6257 | 4.260 |
Why?
| | Male | 83 | 2023 | 3210 | 3.540 |
Why?
| | Diabetes Mellitus, Type 2 | 11 | 2023 | 44 | 3.260 |
Why?
| | Child | 62 | 2023 | 3020 | 3.220 |
Why?
| | Adolescent | 60 | 2023 | 2029 | 3.200 |
Why?
| | Parents | 19 | 2023 | 141 | 3.170 |
Why?
| | Insulin Infusion Systems | 14 | 2023 | 15 | 3.060 |
Why?
| | Female | 71 | 2023 | 3322 | 2.950 |
Why?
| | Prostatic Neoplasms | 7 | 2022 | 9 | 2.640 |
Why?
| | Diabetes Mellitus | 4 | 2023 | 19 | 2.440 |
Why?
| | Depression | 9 | 2022 | 63 | 2.330 |
Why?
| | Adult | 37 | 2023 | 1128 | 2.300 |
Why?
| | Child, Preschool | 32 | 2022 | 1474 | 2.170 |
Why?
| | Hyperglycemia | 7 | 2020 | 8 | 2.150 |
Why?
| | Mass Screening | 5 | 2022 | 42 | 1.690 |
Why?
| | Registries | 13 | 2022 | 80 | 1.650 |
Why?
| | Middle Aged | 26 | 2021 | 555 | 1.640 |
Why?
| | Self Care | 5 | 2018 | 24 | 1.530 |
Why?
| | Caregivers | 5 | 2022 | 37 | 1.510 |
Why?
| | Patient Compliance | 6 | 2017 | 71 | 1.290 |
Why?
| | Diabetic Ketoacidosis | 4 | 2022 | 5 | 1.210 |
Why?
| | Biomedical Technology | 3 | 2023 | 5 | 1.180 |
Why?
| | Aged | 16 | 2021 | 297 | 1.120 |
Why?
| | Medication Adherence | 4 | 2018 | 57 | 1.110 |
Why?
| | Telemedicine | 3 | 2021 | 67 | 1.110 |
Why?
| | Sweden | 14 | 2022 | 27 | 1.040 |
Why?
| | Mobile Applications | 4 | 2020 | 17 | 1.030 |
Why?
| | Magnetic Resonance Imaging | 3 | 2021 | 113 | 1.010 |
Why?
| | Meals | 6 | 2020 | 12 | 1.010 |
Why?
| | Surveys and Questionnaires | 9 | 2023 | 288 | 1.010 |
Why?
| | Thromboembolism | 1 | 2023 | 2 | 0.980 |
Why?
| | Risk Assessment | 5 | 2021 | 129 | 0.970 |
Why?
| | Neuralgia | 1 | 2023 | 1 | 0.960 |
Why?
| | Hyperalgesia | 1 | 2023 | 4 | 0.960 |
Why?
| | Vitamin D Deficiency | 1 | 2022 | 9 | 0.930 |
Why?
| | Time Factors | 3 | 2021 | 258 | 0.930 |
Why?
| | Young Adult | 15 | 2021 | 610 | 0.920 |
Why?
| | Social Support | 1 | 2022 | 38 | 0.890 |
Why?
| | Risk Factors | 10 | 2023 | 394 | 0.890 |
Why?
| | Cost-Benefit Analysis | 1 | 2021 | 36 | 0.840 |
Why?
| | Capillaries | 1 | 2021 | 1 | 0.840 |
Why?
| | Blood Specimen Collection | 1 | 2021 | 4 | 0.840 |
Why?
| | Cost of Illness | 2 | 2020 | 17 | 0.820 |
Why?
| | Family Conflict | 3 | 2021 | 3 | 0.820 |
Why?
| | Insulin-Secreting Cells | 4 | 2023 | 4 | 0.820 |
Why?
| | Retrospective Studies | 8 | 2023 | 1232 | 0.800 |
Why?
| | Self Efficacy | 2 | 2017 | 28 | 0.770 |
Why?
| | Aging | 2 | 2019 | 37 | 0.760 |
Why?
| | Quality Improvement | 2 | 2019 | 59 | 0.740 |
Why?
| | Health Plan Implementation | 1 | 2019 | 10 | 0.740 |
Why?
| | Child Development | 1 | 2019 | 42 | 0.720 |
Why?
| | Diet, Diabetic | 2 | 2015 | 4 | 0.700 |
Why?
| | Prospective Studies | 13 | 2022 | 490 | 0.700 |
Why?
| | Fear | 5 | 2023 | 16 | 0.670 |
Why?
| | Cross-Sectional Studies | 13 | 2022 | 293 | 0.670 |
Why?
| | Adolescent Behavior | 3 | 2016 | 46 | 0.670 |
Why?
| | Feeding Behavior | 2 | 2018 | 51 | 0.640 |
Why?
| | Parenting | 4 | 2018 | 24 | 0.640 |
Why?
| | Quality of Life | 3 | 2022 | 125 | 0.640 |
Why?
| | Follow-Up Studies | 13 | 2022 | 303 | 0.620 |
Why?
| | Reproducibility of Results | 7 | 2023 | 180 | 0.600 |
Why?
| | United States | 9 | 2021 | 630 | 0.600 |
Why?
| | Glucose | 5 | 2021 | 21 | 0.590 |
Why?
| | Biomarkers | 6 | 2021 | 110 | 0.580 |
Why?
| | Child Behavior | 3 | 2016 | 30 | 0.570 |
Why?
| | Albuminuria | 1 | 2015 | 12 | 0.570 |
Why?
| | Algorithms | 1 | 2016 | 94 | 0.570 |
Why?
| | Food | 1 | 2015 | 15 | 0.550 |
Why?
| | Models, Biological | 3 | 2019 | 46 | 0.510 |
Why?
| | Health Education | 1 | 2014 | 39 | 0.490 |
Why?
| | Infant | 11 | 2020 | 1392 | 0.460 |
Why?
| | Insulins | 2 | 2022 | 2 | 0.450 |
Why?
| | Family | 2 | 2022 | 26 | 0.450 |
Why?
| | Minority Groups | 4 | 2019 | 18 | 0.440 |
Why?
| | Treatment Outcome | 7 | 2022 | 622 | 0.440 |
Why?
| | Crohn Disease | 2 | 2022 | 21 | 0.430 |
Why?
| | Sleep | 4 | 2021 | 32 | 0.420 |
Why?
| | Age of Onset | 4 | 2020 | 24 | 0.420 |
Why?
| | Inflammatory Bowel Diseases | 2 | 2021 | 41 | 0.410 |
Why?
| | Cohort Studies | 6 | 2022 | 256 | 0.400 |
Why?
| | Models, Organizational | 1 | 2020 | 9 | 0.390 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2020 | 9 | 0.390 |
Why?
| | Biomedical Research | 1 | 2020 | 22 | 0.380 |
Why?
| | Research Design | 1 | 2020 | 59 | 0.380 |
Why?
| | Dietary Carbohydrates | 2 | 2020 | 4 | 0.380 |
Why?
| | C-Peptide | 4 | 2023 | 5 | 0.380 |
Why?
| | Behavior Therapy | 2 | 2022 | 41 | 0.370 |
Why?
| | Pilot Projects | 3 | 2022 | 123 | 0.360 |
Why?
| | Case-Control Studies | 4 | 2023 | 130 | 0.340 |
Why?
| | Longitudinal Studies | 4 | 2018 | 121 | 0.340 |
Why?
| | Australia | 5 | 2022 | 7 | 0.340 |
Why?
| | Sudden Infant Death | 2 | 1998 | 2 | 0.330 |
Why?
| | Health Knowledge, Attitudes, Practice | 3 | 2018 | 81 | 0.330 |
Why?
| | Austria | 4 | 2020 | 4 | 0.330 |
Why?
| | Germany | 4 | 2020 | 6 | 0.330 |
Why?
| | Prevalence | 4 | 2022 | 141 | 0.320 |
Why?
| | Prostate-Specific Antigen | 3 | 2021 | 3 | 0.320 |
Why?
| | Hope | 2 | 2018 | 3 | 0.320 |
Why?
| | Socioeconomic Factors | 5 | 2020 | 59 | 0.320 |
Why?
| | Parent-Child Relations | 4 | 2022 | 33 | 0.310 |
Why?
| | Ambulatory Care Facilities | 2 | 2019 | 36 | 0.310 |
Why?
| | Incidence | 3 | 2021 | 129 | 0.300 |
Why?
| | Ustekinumab | 2 | 2022 | 2 | 0.280 |
Why?
| | Patient Education as Topic | 4 | 2018 | 64 | 0.270 |
Why?
| | Developed Countries | 3 | 2020 | 3 | 0.270 |
Why?
| | Accelerometry | 2 | 2022 | 40 | 0.270 |
Why?
| | Predictive Value of Tests | 2 | 2015 | 99 | 0.270 |
Why?
| | Aged, 80 and over | 3 | 2020 | 113 | 0.260 |
Why?
| | Motivation | 2 | 2022 | 65 | 0.260 |
Why?
| | Infant, Newborn | 6 | 2020 | 811 | 0.250 |
Why?
| | Proportional Hazards Models | 4 | 2017 | 24 | 0.250 |
Why?
| | Sick Leave | 2 | 2022 | 2 | 0.250 |
Why?
| | Exercise | 2 | 2023 | 114 | 0.250 |
Why?
| | Sex Factors | 4 | 2020 | 76 | 0.250 |
Why?
| | Pediatrics | 2 | 2019 | 173 | 0.250 |
Why?
| | Stress, Psychological | 3 | 2020 | 36 | 0.240 |
Why?
| | Genetic Therapy | 1 | 2023 | 5 | 0.240 |
Why?
| | Interleukin-10 | 1 | 2023 | 5 | 0.240 |
Why?
| | Health Personnel | 2 | 2022 | 25 | 0.240 |
Why?
| | DNA | 1 | 2023 | 71 | 0.240 |
Why?
| | Prediabetic State | 1 | 2022 | 3 | 0.230 |
Why?
| | Prostate | 2 | 2021 | 2 | 0.230 |
Why?
| | Carrier Proteins | 3 | 2017 | 32 | 0.230 |
Why?
| | Cholera | 1 | 2022 | 1 | 0.230 |
Why?
| | Cholera Vaccines | 1 | 2022 | 1 | 0.230 |
Why?
| | Islets of Langerhans | 2 | 2013 | 4 | 0.230 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2022 | 61 | 0.230 |
Why?
| | Self-Injurious Behavior | 1 | 2022 | 2 | 0.220 |
Why?
| | Biomarkers, Tumor | 2 | 2021 | 37 | 0.220 |
Why?
| | Plant Viruses | 1 | 2022 | 1 | 0.220 |
Why?
| | Orchidaceae | 1 | 2022 | 1 | 0.220 |
Why?
| | RNA Viruses | 1 | 2022 | 3 | 0.220 |
Why?
| | Problem Behavior | 1 | 2022 | 8 | 0.220 |
Why?
| | Colitis, Ulcerative | 1 | 2021 | 7 | 0.220 |
Why?
| | Comorbidity | 1 | 2022 | 65 | 0.220 |
Why?
| | Income | 2 | 2020 | 13 | 0.220 |
Why?
| | Quality-Adjusted Life Years | 1 | 2021 | 2 | 0.220 |
Why?
| | Early Detection of Cancer | 1 | 2021 | 6 | 0.210 |
Why?
| | Rh-Hr Blood-Group System | 1 | 2021 | 2 | 0.210 |
Why?
| | Disease Susceptibility | 1 | 2021 | 9 | 0.210 |
Why?
| | ABO Blood-Group System | 1 | 2021 | 10 | 0.210 |
Why?
| | Veins | 1 | 2021 | 4 | 0.210 |
Why?
| | Postprandial Period | 3 | 2020 | 14 | 0.210 |
Why?
| | Inflammation | 2 | 2019 | 47 | 0.210 |
Why?
| | Child Health | 1 | 2021 | 3 | 0.210 |
Why?
| | Conservation of Natural Resources | 1 | 2021 | 1 | 0.210 |
Why?
| | Rainforest | 1 | 2021 | 1 | 0.210 |
Why?
| | Specimen Handling | 1 | 2021 | 18 | 0.210 |
Why?
| | Diabetes Complications | 1 | 2020 | 1 | 0.210 |
Why?
| | Midwestern United States | 5 | 2021 | 41 | 0.200 |
Why?
| | Hospitalization | 1 | 2022 | 183 | 0.200 |
Why?
| | Disease Management | 2 | 2019 | 36 | 0.200 |
Why?
| | Efficiency | 1 | 2020 | 1 | 0.200 |
Why?
| | Dihydroxycholecalciferols | 1 | 2020 | 1 | 0.200 |
Why?
| | Patient Care | 1 | 2020 | 5 | 0.200 |
Why?
| | Glucagon-Secreting Cells | 1 | 2020 | 1 | 0.200 |
Why?
| | Life Change Events | 1 | 2020 | 4 | 0.200 |
Why?
| | Vitamin D | 1 | 2020 | 20 | 0.200 |
Why?
| | Watchful Waiting | 1 | 2020 | 8 | 0.190 |
Why?
| | Risk | 3 | 2015 | 23 | 0.190 |
Why?
| | Health Care Costs | 1 | 2020 | 31 | 0.190 |
Why?
| | Sensitivity and Specificity | 2 | 2022 | 140 | 0.190 |
Why?
| | Adaptation, Psychological | 1 | 2020 | 39 | 0.190 |
Why?
| | Professional Practice | 1 | 2019 | 5 | 0.190 |
Why?
| | Luxembourg | 1 | 2019 | 1 | 0.190 |
Why?
| | Datasets as Topic | 1 | 2019 | 6 | 0.190 |
Why?
| | Health Status Disparities | 1 | 2019 | 22 | 0.190 |
Why?
| | Reference Values | 3 | 2015 | 38 | 0.190 |
Why?
| | Healthcare Disparities | 1 | 2019 | 21 | 0.190 |
Why?
| | Androgen-Binding Protein | 1 | 1999 | 1 | 0.190 |
Why?
| | Monitoring, Physiologic | 1 | 2019 | 23 | 0.190 |
Why?
| | Testosterone | 1 | 1999 | 12 | 0.180 |
Why?
| | Saliva | 1 | 1999 | 10 | 0.180 |
Why?
| | Animals | 7 | 2017 | 853 | 0.180 |
Why?
| | Atherosclerosis | 1 | 2019 | 2 | 0.180 |
Why?
| | Program Evaluation | 1 | 2019 | 52 | 0.180 |
Why?
| | Feeding and Eating Disorders | 1 | 2019 | 9 | 0.180 |
Why?
| | Carbohydrates | 1 | 2018 | 2 | 0.180 |
Why?
| | Authoritarianism | 1 | 2018 | 1 | 0.180 |
Why?
| | Oxidative Stress | 2 | 2015 | 14 | 0.170 |
Why?
| | Nutrition Surveys | 1 | 2018 | 7 | 0.170 |
Why?
| | Dyslipidemias | 1 | 2018 | 14 | 0.170 |
Why?
| | Prognosis | 4 | 2020 | 176 | 0.170 |
Why?
| | Nutritional Status | 1 | 2018 | 15 | 0.170 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2018 | 1 | 0.170 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2018 | 20 | 0.170 |
Why?
| | Eating | 1 | 2018 | 31 | 0.170 |
Why?
| | Papillomavirus Infections | 1 | 2018 | 7 | 0.170 |
Why?
| | Diabetic Angiopathies | 1 | 2017 | 1 | 0.160 |
Why?
| | Endothelium, Vascular | 1 | 2017 | 4 | 0.160 |
Why?
| | Aortic Diseases | 1 | 2017 | 4 | 0.160 |
Why?
| | Factor Analysis, Statistical | 1 | 2017 | 23 | 0.160 |
Why?
| | ROC Curve | 3 | 2022 | 17 | 0.160 |
Why?
| | Stroke | 1 | 2017 | 22 | 0.150 |
Why?
| | Mothers | 1 | 2017 | 32 | 0.150 |
Why?
| | Blood Pressure | 1 | 2017 | 54 | 0.150 |
Why?
| | Health Behavior | 1 | 2017 | 69 | 0.150 |
Why?
| | Hypertension | 1 | 2017 | 57 | 0.150 |
Why?
| | Sleep Deprivation | 1 | 2016 | 1 | 0.150 |
Why?
| | Neoplasm Grading | 3 | 2021 | 5 | 0.150 |
Why?
| | Optimism | 1 | 2015 | 2 | 0.150 |
Why?
| | Heart Failure | 1 | 2015 | 12 | 0.140 |
Why?
| | Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2015 | 1 | 0.140 |
Why?
| | Nutrition Policy | 1 | 2015 | 5 | 0.140 |
Why?
| | Child Nutrition Sciences | 1 | 2015 | 3 | 0.140 |
Why?
| | Metformin | 1 | 2015 | 3 | 0.140 |
Why?
| | Forkhead Transcription Factors | 1 | 2015 | 5 | 0.140 |
Why?
| | Food Supply | 1 | 2015 | 11 | 0.140 |
Why?
| | Osteocalcin | 1 | 2015 | 2 | 0.140 |
Why?
| | Endothelial Cells | 1 | 2015 | 16 | 0.140 |
Why?
| | Kansas | 1 | 2015 | 49 | 0.140 |
Why?
| | Pneumonia, Aspiration | 1 | 2015 | 9 | 0.140 |
Why?
| | Insurance Coverage | 1 | 2015 | 19 | 0.140 |
Why?
| | Genome-Wide Association Study | 1 | 2015 | 106 | 0.130 |
Why?
| | Sunlight | 1 | 2014 | 1 | 0.130 |
Why?
| | Long Interspersed Nucleotide Elements | 1 | 2014 | 1 | 0.130 |
Why?
| | Ultraviolet Rays | 1 | 2014 | 5 | 0.130 |
Why?
| | Calcifediol | 1 | 2014 | 3 | 0.130 |
Why?
| | Lymphocytes | 1 | 2014 | 14 | 0.130 |
Why?
| | Rats | 4 | 2017 | 193 | 0.130 |
Why?
| | Body Mass Index | 1 | 2015 | 144 | 0.130 |
Why?
| | Cyclin D1 | 1 | 2013 | 1 | 0.120 |
Why?
| | Cyclic AMP Response Element-Binding Protein | 1 | 2013 | 4 | 0.120 |
Why?
| | Transcriptional Activation | 1 | 2013 | 12 | 0.120 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2013 | 29 | 0.120 |
Why?
| | Nicotinamide Phosphoribosyltransferase | 1 | 2013 | 8 | 0.120 |
Why?
| | Marital Therapy | 1 | 1993 | 1 | 0.120 |
Why?
| | Double-Blind Method | 2 | 2023 | 44 | 0.120 |
Why?
| | Marriage | 1 | 1993 | 2 | 0.120 |
Why?
| | DNA Methylation | 1 | 2014 | 114 | 0.120 |
Why?
| | Communication | 1 | 1993 | 51 | 0.110 |
Why?
| | RNA, Viral | 2 | 2022 | 19 | 0.110 |
Why?
| | Signal Transduction | 1 | 2013 | 146 | 0.110 |
Why?
| | Gene Expression Regulation | 1 | 2013 | 132 | 0.110 |
Why?
| | Cell Cycle Proteins | 3 | 2017 | 13 | 0.110 |
Why?
| | Cell Proliferation | 2 | 2013 | 70 | 0.110 |
Why?
| | Rats, Sprague-Dawley | 3 | 2017 | 94 | 0.110 |
Why?
| | Remission Induction | 2 | 2022 | 23 | 0.110 |
Why?
| | Islets of Langerhans Transplantation | 1 | 2011 | 1 | 0.110 |
Why?
| | Bone Marrow | 1 | 2011 | 6 | 0.110 |
Why?
| | Graft Survival | 1 | 2011 | 31 | 0.100 |
Why?
| | Pandemics | 2 | 2022 | 76 | 0.100 |
Why?
| | Internationality | 2 | 2021 | 5 | 0.100 |
Why?
| | Cooperative Behavior | 1 | 2020 | 24 | 0.100 |
Why?
| | Anxiety | 2 | 2020 | 43 | 0.090 |
Why?
| | England | 2 | 2020 | 2 | 0.090 |
Why?
| | Norway | 2 | 2020 | 2 | 0.090 |
Why?
| | Wales | 2 | 2020 | 2 | 0.090 |
Why?
| | New Zealand | 2 | 1998 | 4 | 0.080 |
Why?
| | Hepatectomy | 1 | 2007 | 4 | 0.080 |
Why?
| | Mice | 3 | 2015 | 433 | 0.080 |
Why?
| | Hematopoietic Stem Cells | 1 | 2007 | 23 | 0.080 |
Why?
| | Liver Diseases | 1 | 2007 | 14 | 0.080 |
Why?
| | Electronic Health Records | 2 | 2018 | 59 | 0.080 |
Why?
| | Reactive Oxygen Species | 2 | 2017 | 6 | 0.080 |
Why?
| | Liver | 1 | 2007 | 133 | 0.070 |
Why?
| | Combined Modality Therapy | 2 | 2016 | 52 | 0.070 |
Why?
| | Transcription Factors | 2 | 2015 | 92 | 0.070 |
Why?
| | Hospitals, Pediatric | 2 | 2016 | 178 | 0.070 |
Why?
| | Cardiovascular Diseases | 2 | 2015 | 49 | 0.070 |
Why?
| | Sports | 1 | 2004 | 4 | 0.070 |
Why?
| | Athletic Injuries | 1 | 2004 | 3 | 0.070 |
Why?
| | Workload | 1 | 2004 | 8 | 0.070 |
Why?
| | Age Factors | 2 | 2015 | 213 | 0.060 |
Why?
| | RNA, Messenger | 3 | 2013 | 166 | 0.060 |
Why?
| | Insulin, Regular, Human | 1 | 2023 | 1 | 0.060 |
Why?
| | Verapamil | 1 | 2023 | 3 | 0.060 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2015 | 87 | 0.060 |
Why?
| | Space Perception | 1 | 1982 | 2 | 0.060 |
Why?
| | Reference Standards | 1 | 2022 | 15 | 0.060 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2022 | 14 | 0.060 |
Why?
| | Autoantibodies | 1 | 2022 | 9 | 0.060 |
Why?
| | Risk-Taking | 1 | 2022 | 11 | 0.060 |
Why?
| | Travel | 1 | 2022 | 5 | 0.060 |
Why?
| | Interleukin-23 | 1 | 2022 | 2 | 0.060 |
Why?
| | Administration, Oral | 1 | 2022 | 63 | 0.060 |
Why?
| | Plant Diseases | 1 | 2022 | 1 | 0.060 |
Why?
| | Genome, Viral | 1 | 2022 | 4 | 0.060 |
Why?
| | Suicidal Ideation | 1 | 2022 | 7 | 0.060 |
Why?
| | Phylogeny | 1 | 2022 | 20 | 0.060 |
Why?
| | Viral Proteins | 1 | 2022 | 19 | 0.060 |
Why?
| | Disease Progression | 1 | 2022 | 96 | 0.060 |
Why?
| | Executive Function | 1 | 2022 | 11 | 0.060 |
Why?
| | Molecular Sequence Data | 2 | 1999 | 117 | 0.050 |
Why?
| | Image-Guided Biopsy | 1 | 2021 | 1 | 0.050 |
Why?
| | Random Allocation | 1 | 2021 | 8 | 0.050 |
Why?
| | Intention to Treat Analysis | 1 | 2021 | 9 | 0.050 |
Why?
| | Cells, Cultured | 2 | 2015 | 111 | 0.050 |
Why?
| | Blood Donors | 1 | 2021 | 1 | 0.050 |
Why?
| | Kidney Calculi | 1 | 2021 | 1 | 0.050 |
Why?
| | Hypertension, Pregnancy-Induced | 1 | 2021 | 1 | 0.050 |
Why?
| | Chronic Disease | 1 | 2021 | 106 | 0.050 |
Why?
| | Protective Factors | 1 | 2021 | 7 | 0.050 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2022 | 90 | 0.050 |
Why?
| | Bedding and Linens | 2 | 1998 | 2 | 0.050 |
Why?
| | Forests | 1 | 2021 | 1 | 0.050 |
Why?
| | Blood Transfusion | 1 | 2021 | 14 | 0.050 |
Why?
| | Databases, Genetic | 1 | 2021 | 18 | 0.050 |
Why?
| | Seasons | 1 | 2021 | 25 | 0.050 |
Why?
| | Photography | 1 | 2020 | 4 | 0.050 |
Why?
| | Monitoring, Ambulatory | 1 | 2020 | 4 | 0.050 |
Why?
| | Avoidance Learning | 1 | 2020 | 6 | 0.050 |
Why?
| | Benchmarking | 1 | 2020 | 12 | 0.050 |
Why?
| | Survival Analysis | 1 | 2020 | 38 | 0.050 |
Why?
| | Pensions | 1 | 2020 | 1 | 0.050 |
Why?
| | Prostatectomy | 1 | 2020 | 1 | 0.050 |
Why?
| | Radiotherapy | 1 | 2020 | 4 | 0.050 |
Why?
| | Pregnancy | 1 | 2021 | 255 | 0.050 |
Why?
| | Emigrants and Immigrants | 1 | 2019 | 2 | 0.050 |
Why?
| | Infusion Pumps, Implantable | 1 | 2019 | 2 | 0.050 |
Why?
| | Longevity | 1 | 2019 | 3 | 0.050 |
Why?
| | Ambulatory Care | 1 | 2020 | 43 | 0.050 |
Why?
| | Health Educators | 1 | 2019 | 1 | 0.050 |
Why?
| | Feasibility Studies | 1 | 2019 | 61 | 0.050 |
Why?
| | Linear Models | 1 | 2019 | 55 | 0.050 |
Why?
| | Autoradiography | 1 | 1999 | 1 | 0.050 |
Why?
| | Electrophoresis | 1 | 1999 | 1 | 0.050 |
Why?
| | Dihydrotestosterone | 1 | 1999 | 1 | 0.050 |
Why?
| | Dimerization | 1 | 1999 | 4 | 0.050 |
Why?
| | Mice, Inbred DBA | 1 | 1999 | 3 | 0.050 |
Why?
| | Mice, Inbred C3H | 1 | 1999 | 10 | 0.050 |
Why?
| | Delivery of Health Care | 1 | 2019 | 25 | 0.050 |
Why?
| | Amino Acid Sequence | 1 | 1999 | 65 | 0.050 |
Why?
| | Homozygote | 1 | 1999 | 24 | 0.050 |
Why?
| | E-Selectin | 1 | 2019 | 1 | 0.050 |
Why?
| | Carotid Intima-Media Thickness | 1 | 2019 | 6 | 0.050 |
Why?
| | C-Reactive Protein | 1 | 2019 | 16 | 0.050 |
Why?
| | Medical Overuse | 1 | 2018 | 1 | 0.040 |
Why?
| | Biopsy, Large-Core Needle | 1 | 2018 | 3 | 0.040 |
Why?
| | Gene Expression | 2 | 2015 | 72 | 0.040 |
Why?
| | Computers, Handheld | 1 | 2018 | 11 | 0.040 |
Why?
| | User-Computer Interface | 1 | 2018 | 10 | 0.040 |
Why?
| | Denmark | 1 | 2018 | 1 | 0.040 |
Why?
| | Data Collection | 1 | 2018 | 31 | 0.040 |
Why?
| | Scandinavian and Nordic Countries | 1 | 2018 | 1 | 0.040 |
Why?
| | Health Policy | 1 | 2018 | 13 | 0.040 |
Why?
| | Databases as Topic | 1 | 2017 | 2 | 0.040 |
Why?
| | Psychometrics | 1 | 2018 | 31 | 0.040 |
Why?
| | Glycemic Index | 1 | 2017 | 2 | 0.040 |
Why?
| | Genetic Variation | 1 | 1999 | 140 | 0.040 |
Why?
| | Directive Counseling | 1 | 2016 | 6 | 0.040 |
Why?
| | Breast Feeding | 1 | 1996 | 23 | 0.040 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2016 | 7 | 0.040 |
Why?
| | Schools, Veterinary | 1 | 1976 | 1 | 0.040 |
Why?
| | Cholesterol Side-Chain Cleavage Enzyme | 1 | 1995 | 1 | 0.040 |
Why?
| | Gonads | 1 | 1995 | 1 | 0.040 |
Why?
| | Adrenal Glands | 1 | 1995 | 6 | 0.040 |
Why?
| | Diabetic Nephropathies | 1 | 2015 | 3 | 0.040 |
Why?
| | Cause of Death | 1 | 2015 | 11 | 0.040 |
Why?
| | Cholesterol, LDL | 1 | 2015 | 5 | 0.040 |
Why?
| | Peer Influence | 1 | 2015 | 2 | 0.040 |
Why?
| | Diet Records | 1 | 2015 | 6 | 0.040 |
Why?
| | Adenylate Kinase | 1 | 2015 | 1 | 0.040 |
Why?
| | Thioredoxins | 1 | 2015 | 1 | 0.040 |
Why?
| | DNA-Binding Proteins | 1 | 1995 | 74 | 0.040 |
Why?
| | Cell Nucleus | 1 | 2015 | 16 | 0.040 |
Why?
| | Aorta | 1 | 2015 | 7 | 0.040 |
Why?
| | Cytosol | 1 | 2015 | 11 | 0.040 |
Why?
| | Oxidation-Reduction | 1 | 2015 | 25 | 0.040 |
Why?
| | Food Preferences | 1 | 2015 | 12 | 0.030 |
Why?
| | Caspase 7 | 1 | 2015 | 1 | 0.030 |
Why?
| | Caspase 3 | 1 | 2015 | 7 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2015 | 10 | 0.030 |
Why?
| | Cell Survival | 1 | 2015 | 18 | 0.030 |
Why?
| | Critical Illness | 1 | 2015 | 21 | 0.030 |
Why?
| | Mitochondria | 1 | 2015 | 12 | 0.030 |
Why?
| | Blotting, Western | 1 | 2015 | 41 | 0.030 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2015 | 33 | 0.030 |
Why?
| | Cell Line, Tumor | 1 | 2015 | 65 | 0.030 |
Why?
| | Nuclear Proteins | 1 | 2015 | 64 | 0.030 |
Why?
| | Nerve Tissue Proteins | 1 | 2015 | 64 | 0.030 |
Why?
| | Apoptosis | 1 | 2015 | 61 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2015 | 91 | 0.030 |
Why?
| | Micronuclei, Chromosome-Defective | 1 | 2014 | 1 | 0.030 |
Why?
| | Body Temperature Regulation | 1 | 1994 | 1 | 0.030 |
Why?
| | Oxygen Consumption | 1 | 1994 | 10 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2013 | 3 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2013 | 10 | 0.030 |
Why?
| | Phosphorylation | 1 | 2013 | 48 | 0.030 |
Why?
| | Injections, Subcutaneous | 1 | 2013 | 7 | 0.030 |
Why?
| | Time | 1 | 2013 | 6 | 0.030 |
Why?
| | Glucagon | 1 | 2013 | 3 | 0.030 |
Why?
| | Enzyme Activation | 1 | 2013 | 13 | 0.030 |
Why?
| | Proteomics | 1 | 2013 | 15 | 0.030 |
Why?
| | Pancreas | 1 | 2013 | 9 | 0.030 |
Why?
| | Problem Solving | 1 | 1993 | 2 | 0.030 |
Why?
| | Cell Line | 1 | 2013 | 107 | 0.030 |
Why?
| | Protein Binding | 1 | 2013 | 48 | 0.030 |
Why?
| | Health Services Accessibility | 1 | 2013 | 32 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2013 | 41 | 0.030 |
Why?
| | Respiratory Tract Infections | 1 | 1994 | 72 | 0.030 |
Why?
| | Folic Acid | 1 | 2011 | 13 | 0.030 |
Why?
| | Methotrexate | 1 | 2011 | 17 | 0.030 |
Why?
| | Arthritis, Juvenile | 1 | 2011 | 25 | 0.030 |
Why?
| | Glucose Tolerance Test | 1 | 2011 | 3 | 0.030 |
Why?
| | Histocytochemistry | 1 | 2011 | 4 | 0.030 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2011 | 2 | 0.030 |
Why?
| | Coculture Techniques | 1 | 2011 | 3 | 0.030 |
Why?
| | Osteoblasts | 1 | 2011 | 22 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2011 | 101 | 0.030 |
Why?
| | Genotype | 1 | 2011 | 299 | 0.020 |
Why?
| | Pharmacogenetics | 1 | 2011 | 121 | 0.020 |
Why?
| | Integrin alpha6 | 1 | 2007 | 1 | 0.020 |
Why?
| | Oncostatin M | 1 | 2007 | 1 | 0.020 |
Why?
| | ErbB Receptors | 1 | 2007 | 3 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-met | 1 | 2007 | 2 | 0.020 |
Why?
| | Antigens, CD | 1 | 2007 | 6 | 0.020 |
Why?
| | Hepatocytes | 1 | 2007 | 6 | 0.020 |
Why?
| | Cell Separation | 1 | 2007 | 5 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2007 | 6 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2007 | 28 | 0.020 |
Why?
| | Glycoproteins | 1 | 2007 | 10 | 0.020 |
Why?
| | Peptides | 1 | 2007 | 10 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2007 | 56 | 0.020 |
Why?
| | Liver Transplantation | 1 | 2007 | 38 | 0.020 |
Why?
| | Phenotype | 1 | 2007 | 221 | 0.020 |
Why?
| | New South Wales | 1 | 2004 | 1 | 0.020 |
Why?
| | Causality | 1 | 2004 | 10 | 0.020 |
Why?
| | Thinking | 1 | 1982 | 2 | 0.010 |
Why?
| | Psychology, Adolescent | 1 | 1982 | 6 | 0.010 |
Why?
| | Rehabilitation Centers | 1 | 1977 | 2 | 0.010 |
Why?
| | Alcoholism | 1 | 1977 | 5 | 0.010 |
Why?
| | Substance-Related Disorders | 1 | 1977 | 33 | 0.010 |
Why?
| | Agriculture | 1 | 1976 | 1 | 0.010 |
Why?
| | Education, Veterinary | 1 | 1976 | 1 | 0.010 |
Why?
| | Financing, Government | 1 | 1976 | 1 | 0.010 |
Why?
| | School Admission Criteria | 1 | 1976 | 1 | 0.010 |
Why?
| | History, 19th Century | 1 | 1976 | 1 | 0.010 |
Why?
| | Education | 1 | 1976 | 3 | 0.010 |
Why?
| | History, 20th Century | 1 | 1976 | 6 | 0.010 |
Why?
| | Fushi Tarazu Transcription Factors | 1 | 1995 | 1 | 0.010 |
Why?
| | Steroidogenic Factor 1 | 1 | 1995 | 1 | 0.010 |
Why?
| | Zinc Fingers | 1 | 1995 | 5 | 0.010 |
Why?
| | Sequence Homology, Amino Acid | 1 | 1995 | 10 | 0.010 |
Why?
| | Sequence Alignment | 1 | 1995 | 12 | 0.010 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 1995 | 5 | 0.010 |
Why?
| | Repressor Proteins | 1 | 1995 | 12 | 0.010 |
Why?
| | DNA Primers | 1 | 1995 | 37 | 0.010 |
Why?
| | Homeodomain Proteins | 1 | 1995 | 14 | 0.010 |
Why?
| | Placenta | 1 | 1995 | 14 | 0.010 |
Why?
| | Base Sequence | 1 | 1995 | 120 | 0.010 |
Why?
| | Mice, Knockout | 1 | 1995 | 89 | 0.010 |
Why?
| | Adrenal Cortex Hormones | 1 | 1995 | 33 | 0.010 |
Why?
| | Clothing | 1 | 1994 | 1 | 0.010 |
Why?
| | Skin Temperature | 1 | 1994 | 1 | 0.010 |
Why?
| | Temperature | 1 | 1994 | 11 | 0.010 |
Why?
| | Acute Disease | 1 | 1994 | 70 | 0.010 |
Why?
| | Maryland | 1 | 1977 | 3 | 0.000 |
Why?
| | Evaluation Studies as Topic | 1 | 1977 | 7 | 0.000 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|